CYP cynata therapeutics limited

Ann: Investor Presentation, page-273

  1. 4,161 Posts.
    lightbulb Created with Sketch. 1467
    One of the problems.
    Its been well discussed here that the CYP manufacturering provides a cheap alternative to the way MSB manufacture. That I can go along with however the significance may not be as big a problem as people think. Low margin high volume indications may be a different matter. CYPs disadvantage is that the cost of establishing a new line of cells may well be far more substantial. As far as I know CYP have only ever used one donner. This is a huge problem when you are at a stage of discovery. You can not weed out bad lots and further more you can't compare them with better performing lots to understand the differences between them. When you understand the differences you can then go to work making better lots.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
17.0¢
Change
0.015(9.68%)
Mkt cap ! $38.41M
Open High Low Value Volume
15.5¢ 17.0¢ 15.5¢ $47.10K 289.1K

Buyers (Bids)

No. Vol. Price($)
1 50000 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.0¢ 23813 3
View Market Depth
Last trade - 16.10pm 27/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.